542 related articles for article (PubMed ID: 24781518)
1. Antidepressants that inhibit both serotonin and norepinephrine reuptake impair long-term potentiation in hippocampus.
Cooke JD; Cavender HM; Lima HK; Grover LM
Psychopharmacology (Berl); 2014 Dec; 231(23):4429-41. PubMed ID: 24781518
[TBL] [Abstract][Full Text] [Related]
2. Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus.
Cooke JD; Grover LM; Spangler PR
Neuroscience; 2009 Sep; 162(4):1411-9. PubMed ID: 19464349
[TBL] [Abstract][Full Text] [Related]
3. Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants.
Larsen MH; Hay-Schmidt A; Rønn LC; Mikkelsen JD
Eur J Pharmacol; 2008 Jan; 578(2-3):114-22. PubMed ID: 17950272
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiological and neurochemical characterization of the effect of repeated treatment with milnacipran on the rat serotonergic and noradrenergic systems.
Tachibana K; Matsumoto M; Koseki H; Togashi H; Kojima T; Morimoto Y; Yoshioka M
J Psychopharmacol; 2006 Jul; 20(4):562-9. PubMed ID: 16401668
[TBL] [Abstract][Full Text] [Related]
5. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity.
Bath KG; Jing DQ; Dincheva I; Neeb CC; Pattwell SS; Chao MV; Lee FS; Ninan I
Neuropsychopharmacology; 2012 Apr; 37(5):1297-304. PubMed ID: 22218094
[TBL] [Abstract][Full Text] [Related]
6. Comparison of monoamine reuptake inhibitors for the immobility time and serotonin levels in the hippocampus and plasma of sub-chronically forced swim stressed rats.
Abbas G; Naqvi S; Dar A
Pak J Pharm Sci; 2012 Apr; 25(2):441-5. PubMed ID: 22459475
[TBL] [Abstract][Full Text] [Related]
7. Evidence of the dual mechanisms of action of venlafaxine.
Harvey AT; Rudolph RL; Preskorn SH
Arch Gen Psychiatry; 2000 May; 57(5):503-9. PubMed ID: 10807491
[TBL] [Abstract][Full Text] [Related]
8. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents.
Brocco M; Dekeyne A; Veiga S; Girardon S; Millan MJ
Pharmacol Biochem Behav; 2002 Apr; 71(4):667-80. PubMed ID: 11888558
[TBL] [Abstract][Full Text] [Related]
9. Bi-phasic change in BDNF gene expression following antidepressant drug treatment.
Coppell AL; Pei Q; Zetterström TS
Neuropharmacology; 2003 Jun; 44(7):903-10. PubMed ID: 12726822
[TBL] [Abstract][Full Text] [Related]
10. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats.
Mochizuki D; Tsujita R; Yamada S; Kawasaki K; Otsuka Y; Hashimoto S; Hattori T; Kitamura Y; Miki N
Psychopharmacology (Berl); 2002 Jul; 162(3):323-32. PubMed ID: 12122491
[TBL] [Abstract][Full Text] [Related]
11. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat.
Béïque J; de Montigny C; Blier P; Debonnel G
Neuropharmacology; 2000 Jul; 39(10):1813-22. PubMed ID: 10884562
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.
Weikop P; Kehr J; Scheel-Krüger J
J Psychopharmacol; 2007 Nov; 21(8):795-804. PubMed ID: 17984160
[TBL] [Abstract][Full Text] [Related]
13. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
Béïque JC; de Montigny C; Blier P; Debonnel G
Synapse; 1999 Jun; 32(3):198-211. PubMed ID: 10340630
[TBL] [Abstract][Full Text] [Related]
14. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine.
Béïque JC; de Montigny C; Blier P; Debonnel G
Br J Pharmacol; 1998 Oct; 125(3):526-32. PubMed ID: 9806336
[TBL] [Abstract][Full Text] [Related]
15. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of the 5-HT2 receptor antagonist on the anti-immobility effects of noradrenaline and serotonin reuptake inhibitors in the forced swimming test.
Yamada J; Sugimoto Y
Brain Res; 2002 Dec; 958(1):161-5. PubMed ID: 12468041
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
Beyer CE; Boikess S; Luo B; Dawson LA
J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828
[TBL] [Abstract][Full Text] [Related]
18. Milnacipran, a serotonin and noradrenaline reuptake inhibitor, suppresses long-term potentiation in the rat hippocampal CA1 field via 5-HT1A receptors and alpha 1-adrenoceptors.
Tachibana K; Matsumoto M; Togashi H; Kojima T; Morimoto Y; Kemmotsu O; Yoshioka M
Neurosci Lett; 2004 Mar; 357(2):91-4. PubMed ID: 15036582
[TBL] [Abstract][Full Text] [Related]
19. Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNF-induced long-term potentiation.
Alme MN; Wibrand K; Dagestad G; Bramham CR
Neural Plast; 2007; 2007():26496. PubMed ID: 18301726
[TBL] [Abstract][Full Text] [Related]
20. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.
Felton TM; Kang TB; Hjorth S; Auerbach SB
Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):297-305. PubMed ID: 12644903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
